Loading stock data…
RGNX
$10.22+1.00 (+10.85%)
Pre-Market$10.37+0.15 (+1.46%)· Last close May 6
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
REGENXBIO Inc. in the Healthcare sector is trading at $10.22. The stock is currently 37% below its 52-week high of $16.19, remaining 3.1% below its 200-day moving average. Technical signals show neutral RSI of 62 and bullish MACD crossover, explaining why RGNX maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 62) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.22
Potential Upside
5%
Whystock Fair Value$10.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$27.82+172.2%
Range$12.00 – $50.00
Fundamentals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$482.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-170.90%
Volume
Today's trading volume
1.46M
Recent News
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint (EYPT) delivered earnings and revenue surprises of -25.32% and +132.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.
Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.
Denali Therapeutics solved a major challenge in Hunter syndrome treatment. Now it's ready to take its technology further.
Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval
Denali Therapeutics won FDA approval Wednesday for the first new drug in 20 years to treat a rare genetic disease.